
NETRIS Pharma Announces Positive Interim Phase II Results for NP137 in combination with anti-PD(L)1
Confirmation of NP137 Potential to Overcome Resistance to Immune Checkpoint - Clinical Trial Design and Interim Results to be Presented at ASCO and ESMO 2025 LYON, FRANCE, April 25, 2025 /EINPresswire.com/ -- NETRIS Pharma, a clinical-stage …